Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, is hosting a live webinar today at 12:30 p.m. Eastern to outline the growth strategy for its wholly owned subsidiary, Open-Medicine AI (OMAI). The subsidiary is developing a multi-agentic AI platform designed to transform drug development. CEO Panna Sharma will lead the 45-minute session, which will detail OMAI's market opportunity, customer feedback, platform capabilities, development roadmap, economics, benchmarks, potential partnerships, and its contribution to shareholder value. The webinar will include a live demonstration and a question-and-answer session. For full details, see the press release at https://ibn.fm/SpEDF.
The significance of this announcement lies in Lantern's strategic move to commercialize its artificial intelligence expertise through a dedicated platform. OMAI's core capabilities were initially developed within Lantern's clinical programs, leveraging the company's proprietary RADR AI and machine-learning platform. Launched as withZeta.ai in April 2026 with an initial focus on rare cancers, the platform is now expanding into additional diseases, therapy types, and stages of drug development. This expansion could position Lantern to capture a larger share of the growing AI-driven drug discovery market, which is increasingly seen as a way to reduce the cost, time, and failure rates associated with traditional drug development.
By offering OMAI as a multi-agentic AI platform, Lantern is not only advancing its own pipeline but also potentially opening new revenue streams through partnerships and licensing. The platform's ability to integrate large-scale genomic and biological data with advanced machine learning is central to its value proposition, as it aims to identify patients most likely to benefit from therapies and guide biomarker-driven clinical development. Lantern's pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its CNS-focused subsidiary, Starlight Therapeutics. The addition of OMAI as an AI subsidiary underscores the company's commitment to leveraging AI across its operations. The latest updates on LTRN are available in the company's newsroom at https://ibn.fm/LTRN.
The webinar also serves as a platform to showcase OMAI's potential to investors and industry stakeholders, which is critical as competition in AI-driven drug development intensifies. The event is being promoted through AINewsWire, a specialized communications platform focused on AI advancements. AINewsWire is part of the Dynamic Brand Portfolio at IBN, which provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, and enhanced press release enhancement. These channels help ensure that Lantern's message reaches a wide audience of investors and journalists.
For Lantern, the successful rollout of OMAI could be a key differentiator in the biopharmaceutical industry, where AI is increasingly seen as a competitive advantage. The platform's expansion beyond rare cancers into broader disease areas and therapy types suggests a scalable model that could attract partnerships with larger pharmaceutical companies. As the webinar unfolds, investors will be watching for concrete details on OMAI's economics and benchmarks, which will indicate its potential to drive shareholder value. With the AI drug discovery market projected to grow substantially, Lantern's proactive steps to commercialize its technology could yield significant long-term benefits. More information about AINewsWire is available at www.AINewsWire.com, and terms of use and disclaimers can be found at https://www.AINewsWire.com/Disclaimer.
